Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-08-07
2007-08-07
Chen, Stacy B. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S208100
Reexamination Certificate
active
10198938
ABSTRACT:
The invention provides a method of searching for and obtaining a vaccine against the pathogenic effects related to the infection of an animal or human host by a retrovirus that penetrates into a target cell of the host, and a vaccine obtained by the method are provided. The method includes preparing candidate vaccine agents based on a polypeptide comprising at least part of an envelope protein of a pathogenic strain of the retrovirus and selecting as the vaccine a modified polypeptide chosen from polypeptides that induces an immune response directed against an immunodominant region of an envelope protein of the retrovirus and not against a protein of the host.
REFERENCES:
patent: 6455265 (2002-09-01), Serres
patent: 6824783 (2004-11-01), Bolognesi et al.
patent: WO 93 01304 (1993-01-01), None
patent: WO 94 02505 (1994-02-01), None
patent: WO 94 06471 (1994-03-01), None
Steuler et al. Distinct Populations of Human Immunodeficiency Virus Type 1 in Blood and Cerebrospinal Fluid, AIDS Research and Human Retroviruses, 1992, 8(1):53-59.
R. P. Johnson et al., “Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type I envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation,”Journal of Experimental Medicine, Apr. 1, 1992, 175(4) pp. 961-971.
Fahey et al., “Status of immune-based therapies in HIV infection and AIDS,”Clin. Exp. Immunol., vol. 88, pp. 1-5, 1992.
Fox, J. “No winners against AIDS,”Bio/Technology, vol. 12, p. 128, 1994.
Haynes et al., “Update on the Issues of HIV Vaccine Development,”The Finnish Medical Society DUODECIM, Ann Med, vol. 28, pp. 39-41, 1996.
Reiher, Walter E., III, et al., “Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 9188-9192, Dec. 1986.
Bost, K. L., et al., “Individuals infected with HIV possess antibodies against IL-2,” Immunology, vol. 65, pp. 611-615, 1988.
Levy, Jay A., “Pathogenesis of Human Immunodeficiency Virus Infection,” Microbiological Reviews, vol. 57, No. 1, pp. 183-289, Mar. 1993.
Chen Stacy B.
Mymetics SA
Oliff & Berridg,e PLC
LandOfFree
Polynucleotide encoding a mutated HIV gp41 polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotide encoding a mutated HIV gp41 polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide encoding a mutated HIV gp41 polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861334